Life Sciences

  • June 03, 2026

    Balwani Takes Theranos Conviction Challenge To Justices

    Former Theranos executive Ramesh "Sunny" Balwani is asking the U.S. Supreme Court to review his criminal fraud conviction and nearly 13-year prison sentence, arguing that the Ninth Circuit used the wrong review doctrine in rejecting his argument that prosecutors had failed to correct allegedly false testimony given by investor victims.

  • June 03, 2026

    'This Is Their Document': Jury Told J&J Docs Prove Talc Lies

    Counsel for the families of three women who died of ovarian cancer delivered closing arguments Wednesday in their six-week-long bellwether lawsuit against Johnson & Johnson, telling jurors that decades-old internal documents prove the company hid that its talc was contaminated with asbestos.

  • June 03, 2026

    Squires Institutes 3 Patent Reviews, Denies 3 Others

    U.S. Patent and Trademark Office Director John Squires on Tuesday granted three requests for review of patents under the America Invents Act, while turning down three other petitions.

  • June 03, 2026

    Ill. Court Blocks Fla. Suit Targeting Gender Care Policies

    An Illinois federal judge blocked the Florida attorney general's lawsuit targeting medical groups' policies on youth gender-affirming care, saying there's sufficient jurisdiction over Sunshine State officials because of a potential nationwide chilling effect the enforcement action caused.

  • June 03, 2026

    Trans Youth Sue NYU Langone, DOJ To Bar Records Release

    A group of transgender minors and young adults who received gender dysphoria care at NYU Langone urged a New York federal court to bar the U.S. Department of Justice from accessing their sensitive health records through a criminal subpoena.

  • June 03, 2026

    Purdue Pharma Heir Sues Son Over Sackler Matriarch's Estate

    Former Purdue Pharma LP President Richard Sackler has appealed a Connecticut probate court decision favoring his son David Sackler in a dispute over his mother Beverly Sackler's estate, saying a judge ignored self-dealing rules when approving his son's request to assign trust interests to a public charity.

  • June 03, 2026

    BigLaw Insider Trading Defendants Have Big-Name Legal Help

    An insider trading case involving nonpublic information prosecutors say was stolen from some of the largest law firms in the U.S. has ensnared more than two dozen defendants, many of whom have turned to lawyers with notable clients including Donald Trump, Harvey Weinstein and Luigi Mangione.

  • June 03, 2026

    1st Circ. Panel Seems Poised To Uphold RI Drug Pricing Law

    The majority of a First Circuit panel seemed unlikely Wednesday to upend a Rhode Island law that blocks drug manufacturers from imposing restrictions on healthcare providers and contract pharmacies in a federal prescription drug discount program, appearing unconvinced of an argument that states can't interfere with federal government programs. 

  • June 03, 2026

    Supplier Can't Force Arbitration Of Worker's Wage Suit

    A proposed wage class action against a medical and industrial gas supplier can proceed in court, a Washington federal judge ruled, finding that a former worker's arbitration agreement with a staffing agency did not apply.

  • June 03, 2026

    IVF Patients Say Natera Profited Off Ineffective Embryo Tests

    A proposed class of in vitro fertilization patients are suing Natera Inc. in California federal court, alleging that it falsely advertised the efficacy and importance of its preimplantation genetic testing to rake in hundreds of millions of dollars from patients looking to conceive.

  • June 03, 2026

    Drug Research Co. Inotiv Files Ch. 11 To Cut $325M In Debt

    Contract drug research and development company Inotiv Inc. filed a prepackaged Chapter 11 case Wednesday in Texas bankruptcy court with $489 million of debt and support from the majority of its creditors for its reorganization plan.

  • June 03, 2026

    Paul Weiss Hires Deals Pro From Dechert In NY

    Paul Weiss Rifkind Wharton & Garrison LLP announced Monday that it has welcomed a corporate partner from Dechert LLP, touting his role in large mergers and acquisitions in the life sciences, financial services, consumer and retail, energy, technology and industrial sectors.

  • June 02, 2026

    Talc Tester Says J&J Never Pressured Him To Hide Asbestos

    A geologist on Tuesday told a California jury considering bellwether claims that Johnson & Johnson's talc products caused their deadly ovarian cancer that he tested the products for years and the company never asked him to lie about any results, even after he discovered asbestos in a World War II-era bottle.

  • June 02, 2026

    Generics Makers Tell 3rd Circ. Buyers Too Few For Class

    Two pharmaceutical companies embroiled in decadelong litigation over the alleged price-fixing of generic drugs told a Third Circuit panel on Tuesday that groups of drug buyers either didn't have the numbers necessary to support class certification or were not clearly identifiable.

  • June 02, 2026

    FTC Sues Supplement Co. Over Mental Health, Income Claims

    The Federal Trade Commission on Tuesday sued dietary supplement brand Amare Global Holdings Inc. in California federal court, alleging it misleads buyers by falsely claiming its products can treat mental health issues, while also misleading prospective "brand partners" about how much they are likely to make under Amare's program.

  • June 02, 2026

    DLA Piper Brings On A&O Shearman M&A Partner In SF

    DLA Piper has announced it is pushing forward with its "strategic expansion" in Northern California with the addition of "a market-leading dealmaker" from Allen Overy Shearman Sterling.

  • June 02, 2026

    Pharma Co. Inks $7M Deal To End Investor's Cancer Study Suit

    A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.

  • June 02, 2026

    Judge Ends Nausea Drug Suit After Invalidating Other Patents

    A federal judge has ruled one set of patents covering the nausea drug Cinvanti was invalid and found a set asserted in another suit not infringed.

  • June 02, 2026

    Lack Of Indemnity Liability Doomed Vax IP Case, Judge Says

    Drug developer Acuitas Therapeutics Inc. failed to show that it would have to indemnify BioNTech as a result of GlaxoSmithKline's patent infringement lawsuit against BioNTech and Pfizer over the COVID-19 vaccine, a Delaware federal judge has said.

  • June 02, 2026

    Chinese Protein Testing Tech Infringes US Patents, Co. Says

    A U.S. biotechnology company told the U.S. International Trade Commission that a Chinese company is importing and selling kits and other technology in the U.S. that infringe patents related to testing the proteins in genomes, and requested that the products be banned from entering the country.

  • June 01, 2026

    3rd Circ. Preview: AI Copyright Spat, NJ Gun Law Battle

    A copyright fight over the future of AI‑powered legal research heads to the Third Circuit, where a legal publisher will argue this month that a legal technology company's use of its headnotes does not constitute fair use of copyrighted material. The court will also take up a challenge to New Jersey's firearm nuisance law in a case that asks when a trade group can bring a federal suit over a state statute.

  • June 01, 2026

    Albertsons Had Duty To Curb Opioid Diversion, Judge Rules

    As providers of controlled substances, pharmacy giants Albertsons and Safeway had legal duties to prevent the diversion of opioid drugs, a Washington state judge ruled on Monday, though whether the companies failed to fulfill those duties will be determined at trial.

  • June 01, 2026

    Justices Say 11th Circ. Wrong To Consider Posttrial DNA Test

    The U.S. Supreme Court on Monday vacated an Eleventh Circuit opinion that denied habeas relief to a Florida man on death row, saying the appellate court erroneously considered a posttrial DNA analysis that was never seen by the jurors who convicted him.

  • June 01, 2026

    'We Wouldn't Be Alive' If Talc Could Reach Ovaries, Jury Told

    A University of California San Diego gynecologic oncologist told a California jury Monday in a bellwether trial over claims that Johnson & Johnson's talc products caused three women's deadly ovarian cancer that women and girls "wouldn't be alive" if talc could easily migrate to the ovaries because they'd be dying from sepsis.

  • June 01, 2026

    Valeant Investors Should Get Cert. In PwC Fight, Report Says

    A special master recommended Monday that a New Jersey federal judge certify a class of Valeant Pharmaceuticals stockholders looking to hold PwC liable for missing "red flags" that could have caught what they called market manipulation by the pharmaceutical company, rejecting the professional services giant's argument that the lead plaintiff's claims are atypical and "lawyer-driven."

Expert Analysis

  • 2025 Legal Milestones That Will Shape Psychedelics Sector

    Author Photo

    As 2025 draws to a close, psychedelic drug development stands at an inflection point, experiencing unprecedented momentum through recent sweeping regulatory changes and landmark clinical milestones, amid rapidly evolving regulatory expectations, say Odette Hauke at Odette Alina LLC and Kimberly Chew at Husch Blackwell.

  • Series

    Nature Photography Makes Me A Better Lawyer

    Author Photo

    Nature photography reminds me to focus on what is in front of me and to slow down to achieve success, and, in embracing the value of viewing situations through different lenses, offers skills transferable to the practice of law, says Brian Willett at Saul Ewing.

  • What Defense Teams Must Know About PFAS Testing Methods

    Author Photo

    Whether testing for per- and polyfluoroalkyl substances produces results meaningful for litigation depends on the validity of the sampling methodology — so effectively defending these claims requires understanding the scientific and legal implications of different PFAS testing protocols, say attorneys at Hollingsworth.

  • Series

    Law School's Missed Lessons: Practical Problem Solving

    Author Photo

    Issue-spotting skills are well honed in law school, but practicing attorneys must also identify clients’ problems and true goals, and then be able to provide solutions, says Mary Kate Hogan at Quarles & Brady.

  • Intellectual Property Challenges In AI-Driven Drug Discovery

    Author Photo

    Given the adoption of artificial intelligence-based drug discovery platforms and the U.S. Patent and Trademark Office's recent guidance on determining inventorship in AI-assisted inventions, practitioners must consider unprecedented questions regarding inventorship, patentability standards and infringement liability, says Paul Calvo at Sterne Kessler.

  • Reel Justice: 'The Mastermind' And Juror Decision-Making

    Author Photo

    The recent art heist film “The Mastermind” forces viewers to discern the protagonist’s ambiguous motives and reconcile contradictions, offering lessons for attorneys about how a well-crafted trial narrative can tap into the psychological phenomena underlying juror decision-making, says Veronica Finkelstein at Wilmington University.

  • Learning From 2025 FCA Trends Targeting PE In Healthcare

    Author Photo

    False Claims Act enforcement trends and legislative developments from this year signal intensifying state and federal scrutiny of private equity's growing footprint in healthcare, and the urgency of compliance, says Lisa Re at Arnold & Porter.

  • Software Patents May Face New Eligibility Scrutiny

    Author Photo

    November guidance from the U.S. Patent and Trademark Office, along with recent litigation trends from the Federal Circuit, may encourage new challenges in the USPTO and district courts to artificial intelligence and software patents that rely on generic computing functions without concrete details, say attorneys at Venable.

  • Opinion

    A Uniform Federal Rule Would Curb Gen AI Missteps In Court

    Author Photo

    To address the patchwork of courts’ standing orders on generative artificial intelligence, curbing abuses and relieving the burden on judges, the federal judiciary should consider amending its civil procedure rules to require litigants to certify they’ve reviewed legal filings for accuracy, say attorneys at Shook Hardy.

  • Riding The Changing Winds For AI Innovations At The USPTO

    Author Photo

    As recent U.S. Patent and Trademark Office moves reshape how artificial intelligence inventions will be examined and put them on firmer eligibility footing, practitioners need to consider how this shift is both an opportunity and a challenge, say Ryan Phelan at Marshall Gerstein and attorney Mark Campagna.

  • Series

    The Law Firm Merger Diaries: Integrating Practice Groups

    Author Photo

    Enacting unified leadership and consistent client service standards ensures law firm practice groups connect and collaborate around shared goals, turning a law firm merger into a platform for growth rather than a period of disruption, says Brian Catlett at Fennemore Craig.

  • Opinion

    Supreme Court Term Limits Would Carry Hidden Risk

    Author Photo

    While proposals for limiting the terms of U.S. Supreme Court justices are popular, a steady stream of relatively young, highly marketable ex-justices with unique knowledge and influence entering the marketplace of law and politics could create new problems, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.

  • Next Steps For Orgs. Amid Updated OpenAI Usage Policies

    Author Photo

    OpenAI's updates to its usage policies, clarifying that its tools are not substitutes for professional medical, legal or other regulated advice, sends a clear signal that organizations should mirror this clarity in their governance policies to mitigate compliance and liability exposure, say attorneys at Baker Donelson.

  • Series

    Knitting Makes Me A Better Lawyer

    Author Photo

    Stretching my skills as a knitter makes me a better antitrust attorney by challenging me to recalibrate after wrong turns, not rush outcomes, and trust that I can teach myself the skills to tackle new and difficult projects — even when I don’t have a pattern to work from, says Kara Kuritz at V&E.

  • How 11th Circ.'s Qui Tam Review Could Affect FCA Litigation

    Author Photo

    On Dec. 12, the Eleventh Circuit will hear arguments in U.S. ex rel. Zafirov v. Florida Medical Associates, setting the stage for a decision that could drastically reduce enforcement under the False Claims Act, and presenting an opportunity to seek U.S. Supreme Court review of the act's whistleblower provisions, say attorneys at Epstein Becker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.